You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 23, 2024

~ Buy the NUZYRA (omadacycline tosylate) Drug Profile, 2024 PDF Report in the Report Store ~

NUZYRA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


DrugPatentWatch® Generic Entry Outlook for Nuzyra

Nuzyra was eligible for patent challenges on October 2, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 2, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

Summary for NUZYRA
International Patents:247
US Patents:9
Applicants:1
NDAs:2
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 36
Clinical Trials: 5
Patent Applications: 151
Drug Prices: Drug price information for NUZYRA
What excipients (inactive ingredients) are in NUZYRA?NUZYRA excipients list
DailyMed Link:NUZYRA at DailyMed
Drug patent expirations by year for NUZYRA
Drug Prices for NUZYRA

See drug prices for NUZYRA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for NUZYRA
Generic Entry Dates for NUZYRA*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW
NDA:
Dosage:
POWDER;INTRAVENOUS
Generic Entry Dates for NUZYRA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NUZYRA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Paratek Pharmaceuticals IncPhase 3
Hartford HospitalPhase 1
Paratek Pharmaceuticals IncPhase 1

See all NUZYRA clinical trials

Pharmacology for NUZYRA

US Patents and Regulatory Information for NUZYRA

NUZYRA is protected by ten US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of NUZYRA is ⤷  Sign Up.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting NUZYRA

9-aminomethyl minocycline compounds and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF SUBJECTS HAVING BACTERIAL SKIN OR SKIN STRUCTURE INFECTION

Minocycline compounds and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTION

9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA

9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA

9-aminomethyl substituted minocycline compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Minocycline compounds and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Minocycline compounds and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS

Oral and injectable formulations of tetracycline compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Minocycline compounds and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS

FDA Regulatory Exclusivity protecting NUZYRA

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Paratek Pharms Inc NUZYRA omadacycline tosylate POWDER;INTRAVENOUS 209817-001 Oct 2, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Paratek Pharms Inc NUZYRA omadacycline tosylate TABLET;ORAL 209816-001 Oct 2, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Paratek Pharms Inc NUZYRA omadacycline tosylate POWDER;INTRAVENOUS 209817-001 Oct 2, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Paratek Pharms Inc NUZYRA omadacycline tosylate POWDER;INTRAVENOUS 209817-001 Oct 2, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Paratek Pharms Inc NUZYRA omadacycline tosylate TABLET;ORAL 209816-001 Oct 2, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Paratek Pharms Inc NUZYRA omadacycline tosylate POWDER;INTRAVENOUS 209817-001 Oct 2, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Paratek Pharms Inc NUZYRA omadacycline tosylate TABLET;ORAL 209816-001 Oct 2, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NUZYRA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Paratek Pharms Inc NUZYRA omadacycline tosylate POWDER;INTRAVENOUS 209817-001 Oct 2, 2018 ⤷  Sign Up ⤷  Sign Up
Paratek Pharms Inc NUZYRA omadacycline tosylate TABLET;ORAL 209816-001 Oct 2, 2018 ⤷  Sign Up ⤷  Sign Up
Paratek Pharms Inc NUZYRA omadacycline tosylate TABLET;ORAL 209816-001 Oct 2, 2018 ⤷  Sign Up ⤷  Sign Up
Paratek Pharms Inc NUZYRA omadacycline tosylate POWDER;INTRAVENOUS 209817-001 Oct 2, 2018 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for NUZYRA

When does loss-of-exclusivity occur for NUZYRA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 6001
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 09229174
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 0909211
Estimated Expiration: ⤷  Sign Up

Patent: 2020011180
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 19751
Estimated Expiration: ⤷  Sign Up

Patent: 84301
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 10000281
Estimated Expiration: ⤷  Sign Up

China

Patent: 2046177
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 00935
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0180836
Estimated Expiration: ⤷  Sign Up

Patent: 0201883
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 20240
Estimated Expiration: ⤷  Sign Up

Patent: 23382
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 71348
Estimated Expiration: ⤷  Sign Up

Patent: 48258
Estimated Expiration: ⤷  Sign Up

Ecuador

Patent: 10010576
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 71348
Estimated Expiration: ⤷  Sign Up

Patent: 48258
Estimated Expiration: ⤷  Sign Up

Patent: 89030
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 57928
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 38257
Estimated Expiration: ⤷  Sign Up

Patent: 52201
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 40119
Estimated Expiration: ⤷  Sign Up

Patent: 12521
Estimated Expiration: ⤷  Sign Up

Patent: 77645
Estimated Expiration: ⤷  Sign Up

Patent: 11515473
Estimated Expiration: ⤷  Sign Up

Patent: 14221820
Estimated Expiration: ⤷  Sign Up

Patent: 16145260
Estimated Expiration: ⤷  Sign Up

Patent: 18203778
Estimated Expiration: ⤷  Sign Up

Patent: 19196408
Estimated Expiration: ⤷  Sign Up

Patent: 21167355
Estimated Expiration: ⤷  Sign Up

Patent: 23144043
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 71348
Estimated Expiration: ⤷  Sign Up

Patent: 48258
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 10010585
Estimated Expiration: ⤷  Sign Up

Morocco

Patent: 275
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 8428
Estimated Expiration: ⤷  Sign Up

Norway

Patent: 71348
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 71348
Estimated Expiration: ⤷  Sign Up

Patent: 48258
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 71348
Estimated Expiration: ⤷  Sign Up

Patent: 48258
Estimated Expiration: ⤷  Sign Up

Russian Federation

Patent: 10144130
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 71348
Estimated Expiration: ⤷  Sign Up

Patent: 48258
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 1007013
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 1746228
Estimated Expiration: ⤷  Sign Up

Patent: 1835574
Estimated Expiration: ⤷  Sign Up

Patent: 1893740
Estimated Expiration: ⤷  Sign Up

Patent: 110008057
Estimated Expiration: ⤷  Sign Up

Patent: 160105532
Estimated Expiration: ⤷  Sign Up

Patent: 180026799
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 74708
Estimated Expiration: ⤷  Sign Up

Patent: 36448
Estimated Expiration: ⤷  Sign Up

Tunisia

Patent: 10000445
Estimated Expiration: ⤷  Sign Up

Turkey

Patent: 1806893
Estimated Expiration: ⤷  Sign Up

Ukraine

Patent: 9627
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NUZYRA around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 1482926 COMPOSES A BASE DE TETRACYCLINE A SUBSTITUTION AMINOMETHYLE (AMINO-METHYL SUBSTITUTED TETRACYCLINE COMPOUNDS) ⤷  Sign Up
European Patent Office 2301534 Composés de tétracycline à substitution amino-méthyle (Amino-methyl substituted tetracycline compounds) ⤷  Sign Up
Japan 2022189916 テトラサイクリン化合物の塩および多型体 ⤷  Sign Up
Denmark 3348258 ⤷  Sign Up
Russian Federation 2760186 9-АМИНОМЕТИЛМИНОЦИКЛИНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ (9-AMINOMETHYLMINOCYCLINE COMPOUNDS AND THEIR APPLICATION) ⤷  Sign Up
Japan 2019532976 9−アミノメチルミノサイクリン化合物及び市中感染型細菌性肺炎(CABP)の治療におけるその使用 ⤷  Sign Up
Mexico 2019005070 COMPUESTOS DE 9-AMINOMETIL MINOCICLINA Y SU USO EN EL TRATAMIENTO DE NEUMONÍA BACTERIANA ADQUIRIDA EN LA COMUNIDAD (CABP). (9-AMINOMETHYL MINOCYCLINE COMPOUNDS AND USE THEREOF IN TREATING COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP).) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.